TG Therapeutics, Inc. (TGTX)

TG Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Cash & Equivalents	76.77	94.22	103.58	300.15	554.7	113.89
Short-Term Investments	134.31	124.58	59.37	15.88	51.99	27.8
Cash & Cash Equivalents	211.07	218.79	162.95	316.03	606.69	141.69
Cash Growth	49.71%	34.27%	-48.44%	-47.91%	328.19%	102.00%
Receivables	64.98	51.09	0	1.39	0	0
Inventory	77.72	39.82	0	0	0	0
Other Current Assets	6.81	8.23	5.32	13.55	5.06	7.47
Total Current Assets	360.58	317.94	168.27	330.97	611.74	149.15
Property, Plant & Equipment	9.33	9.56	10.82	11.07	11.84	11.81
Long-Term Investments	1.32	0	12.4	35.53	0	0
Goodwill and Intangibles	0.8	0.8	0.8	0.8	0.8	0.8
Other Long-Term Assets	1.29	1.29	1.27	1.26	1.26	1.25
Total Long-Term Assets	12.74	11.64	25.3	48.66	13.9	13.86
Total Assets	373.32	329.59	193.57	379.63	625.64	163.01
Accounts Payable	87.27	38.47	42.02	51.29	37.01	30.04
Deferred Revenue	6.62	6.17	0.31	0.46	0.61	0.76
Current Debt	0	0	0	0.98	22.18	0
Other Current Liabilities	5.8	9.08	10.88	12.66	27.75	53.65
Total Current Liabilities	99.68	53.72	53.2	65.38	87.55	84.45
Long-Term Debt	110.29	109.35	81.48	76.64	18.13	39.19
Other Long-Term Liabilities	3.24	6.02	0.31	0.46	0.61	0.76
Total Long-Term Liabilities	113.53	115.37	81.78	77.09	18.74	39.95
Total Liabilities	213.21	169.09	134.99	142.48	106.29	124.4
Total Debt	110.29	109.35	81.48	77.61	40.31	39.19
Debt Growth	3.48%	34.21%	4.99%	92.55%	2.86%	-
Retained Earnings	-1,525.07	-1,514.36	-1,527.03	-1,328.7	-980.6	-701.22
Shareholders' Equity	160.11	160.5	58.59	237.15	519.35	38.62
Net Cash / Debt	100.79	109.44	81.47	238.42	566.38	102.5
Net Cash / Debt Growth	192.95%	34.33%	-65.83%	-57.90%	452.57%	46.13%
Net Cash Per Share	0.69	0.74	0.60	1.80	4.91	1.16
Working Capital	260.9	264.22	115.07	265.58	524.19	64.7
Book Value Per Share	1.09	1.13	0.43	1.79	4.50	0.44

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).